Short Interest in Femasys Inc. (NASDAQ:FEMY) Grows By 64.2%

Femasys Inc. (NASDAQ:FEMY) was the recipient of a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 434,999 shares, an increase of 64.2% from the July 30th total of 264,928 shares. Currently, 5.6% of the company’s stock are short sold. Based on an average daily volume of 274,553 shares, the days-to-cover ratio is presently 1.6 days.

Femasys Price Performance

Shares of FEMY opened at $3.26 on Wednesday. The firm has a market cap of $27.32 million, a PE ratio of -0.92 and a beta of -2.07. The company has a current ratio of 2.14, a quick ratio of 0.55 and a debt-to-equity ratio of 0.89. The firm has a fifty day simple moving average of $3.23 and a two-hundred day simple moving average of $6.62. Femasys has a 1-year low of $2.02 and a 1-year high of $22.20.

Femasys (NASDAQ:FEMY) last released its quarterly earnings results on Friday, August 14th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%.The firm had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.73 million.

Insider Transactions at Femasys

In other news, CEO Kathy Lee-Sepsick acquired 15,625 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $3.20 per share, with a total value of $50,000.00. Following the transaction, the chief executive officer owned 15,625 shares of the company’s stock, valued at $50,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Dov Elefant acquired 15,625 shares of Femasys stock in a transaction on Friday, August 7th. The shares were purchased at an average price of $3.20 per share, with a total value of $50,000.00. Following the completion of the purchase, the chief financial officer owned 15,625 shares in the company, valued at $50,000. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 38,750 shares of company stock worth $124,000. 7.75% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of FEMY. Geode Capital Management LLC grew its stake in shares of Femasys by 50.8% during the 4th quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock valued at $224,000 after purchasing an additional 131,052 shares during the period. Banco BTG Pactual S.A. purchased a new stake in shares of Femasys during the 4th quarter valued at about $88,000. Jane Street Group LLC bought a new position in shares of Femasys in the 2nd quarter worth approximately $82,000. State Street Corp lifted its stake in shares of Femasys by 43.5% in the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after purchasing an additional 24,500 shares during the period. Finally, Osaic Holdings Inc. bought a new position in shares of Femasys in the 2nd quarter worth approximately $45,000. 65.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on FEMY. Wall Street Zen lowered shares of Femasys from a “hold” rating to a “sell” rating in a report on Saturday, August 22nd. Weiss Ratings downgraded Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. Lake Street Capital reduced their target price on Femasys to $10.00 and set a “buy” rating for the company in a report on Tuesday, August 18th. Finally, Maxim Group decreased their price target on Femasys to $10.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Femasys presently has an average rating of “Moderate Buy” and a consensus price target of $50.00.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.